Categories
All News Energy News Politics Sports

Chronic Lower Back Pain Pipeline Insight 2021 by DelveInsight

 

Chronic lower Back Pain Pipeline” report has been added to DelveInsight

Chronic lower Back Pain Pipeline analysis across different stages of development (Phase III & Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities

Download free sample copyhttps://www.delveinsight.com/sample-request/chronic-lower-back-pain-pipeline-insight

About Chronic Lower Back Pain Disease

Chronic low back pain (CLBP) is a pain that persists for 12 weeks or longer, even after an initial injury or underlying cause of acute low back pain has been treated. Low back pain is widespread, and at one point, everyone might have faced it; however, the exact cause of lower back pain is unknown. Lower back pain that is long-term (for more than 3 months) is called chronic low back pain, this condition might originate from an injury, disease, or stress on different structures of the body, and may vary significantly and felt as bone pain, nerve pain, or muscle pain. LBP can be broadly classified as, Non-specific muscular pain, Muscle spasms, and Radicular pain.

Chronic Lower Back Pain Symptoms

Symptoms range from a dull ache to a stabbing or shooting sensation. The pain may make it hard to move or stand up straight. Pain that lasts more than three months is considered chronic. Other warning signs include a loss of bowel or bladder control, numbness in the groin area, leg weakness, fever, and pain when coughing or urinating

Chronic Lower Back Pain Treatment

Chronic back pain is most often treated with a stepped care approach, moving from simple low-cost treatments to more aggressive approaches. Specific treatments may depend on the identified cause of the back pain. Medications may include:

  • Analgesics and NSAIDS
  • Opioid drugs
  • Anticonvulsants
  • Antidepressants

Other treatments include Surgery, Vertebroplasty and kyphoplasty, Spinal laminectomy, Discectomy and microdiscectomy, Foraminotomy, Nucleoplasty, Radiofrequency denervation, Spinal fusion

Chronic Lower Back Pain Pipeline Report

When assessing CLBP, clinicians should inquire about pain onset, severity, chronicity, and other factors such as pain experience. Pain severity may form a bi-dimensional or a one-dimensional scale depending on the specific instruments tested. High inter-correlations between pain-intensity and pain-related disability measures support the concept of using them as a unitary construct of pain severity. Experts use various scales to assess the severity of pain in CLBP patients; two of the most widely used are Visual Analogue Scale (VAS) and Verbal Rating Scale (VRS).

Marketed drugs included in the report

  • Cymbalta (Duloxetine): Eli Lilly and Company
  • Xtampza: Collegium Pharmaceutical
  • Butrans (buprenorphine): Purdue Pharma
  • Belbuca: BioDelivery Sciences International

Emerging drugs included in the report

  • Tanezumab: Eli Lilly/Pfizer
  • Fasinumab: Regeneron Pharmaceuticals/Teva Pharmaceuticals
  • MPC-06-ID (Rexlemestrocel-L): Mesoblast
  • CAM2038: Braeburn Pharmaceuticals/Camurus
  • Egalet-002: Egalet Corporation
  • ALLOD-2: Allodynic Therapeutics
  • ASP7962: Astellas Pharma Europe B.V.
  • AXS-02 (disodium zoledronate tetrahydrate): Axsome Therapeutics

Chronic Lower Back Pain Key Players

  • Persica Pharmaceuticals Ltd.
  • Micron Research Ltd.
  • Mesoblast, Ltd.
  • Allogenic BM-MSCs Injection
  • AnGes, Inc.

Chronic Lower Back Pain Pipeline: Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Lower Back Pain R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Lower Back Pain.
  • June 2020: New therapy reduces chronic low back pain in large international study
  • A new study has found that tanezumab, a monoclonal antibody that inhibits nerve activity, provides relief in patients with chronic low back pain, one of the leading reasons why people seek medical care and the number one cause of disability worldwide. Researchers are increasingly finding that certain proteins circulating in the bloodstream heighten the sensitivity of cells in the nervous system to pain. One of these proteins, called nerve growth factor (NGF), may explain why some individuals experience more intense and chronic back pain. Tanezumab is an NGF inhibitor.
  • June 2020: Relievant Announces Publication of 5-Year Data Demonstrating Long Term Clinical Benefits of the Intracept Procedure in Chronic Low Back Pain Patients

Relievant Medsystems announced European Spine Journal publication of long-term data from the Level I SMART trial showing durability of improvements in pain and function beyond 5 years for patients treated with the Intracept procedure. The recently published long-term studyi is a single-arm, open-label, prospective follow-up of 100 US patients (85% retention) who were successfully treated with basivertebral nerve ablation in the SMART randomized study. Mean patient follow-up was 6.4 years post-procedure (range: 5.4 – 7.8 years). The study evaluated functional impact using the Oswestry Disability Index (ODI), low back pain scores using a Visual Analog Scale (VAS), pain interventions post-BVN ablation, and patient satisfaction.

Download free sample copy- https://www.delveinsight.com/sample-request/chronic-lower-back-pain-pipeline-insight

Following is the table of content of Chronic Lower Back Pain pipeline report

  • Introduction
  • Executive Summary
  • Chronic Lower Back Pain: Overview
  • Pipeline Therapeutics
  • Therapeutic Assessment
  • Chronic Lower Back Pain – DelveInsight’s Analytical Perspective
  • In-depth Commercial Assessment
  • Chronic Lower Back Pain Collaboration Deals
  • Late Stage Products (Phase III)
  • Rexlemestrocel-L: Mesoblast, Ltd.
  • Late Stage Products (Phase II/III)
  • Allogenic BM-MSCs Injection: BG Klinikum Bergmannstrost
  • Mid Stage Products (Phase II)
  • NNC0365-3769 A (Mim8): Novo Nordisk A/S
  • Early Stage Products (Phase I/II)
  • PP353: Persica Pharmaceuticals Ltd.
  • Early Stage Products (Phase I)
  • AMG0103: AnGes, Inc.
  • Chronic Lower Back Pain- Market Drivers and Barriers
  • Appendix

Chronic Lower Back Pain Pipeline: Key Questions

  • How many companies are developing Chronic Lower Back Pain drugs?
  • How many Chronic Lower Back Pain drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Lower Back Pain?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Lower Back Pain therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chronic Lower Back Pain and their status?
  • What are the key designations that have been granted to the emerging drugs?

Related Reports

https://jumbonews.co.uk/